By : JD staff writer
Jordan Daily – Dar Aldawa, the Jordanian pharmaceutical company, reported a net profit after tax of JD 3.74 million in 2024, marking a 21% increase from JD 3.09 million in 2023, according to unaudited financial results.
The profit growth was primarily driven by an 8.4% increase in net sales, which added JD 3.86 million to the company’s gross profit. Dar Aldawa’s working capital rose to JD 9.76 million, up from JD 7.58 million in the previous year.
His Majesty King Abdullah II visited Dar Aldawa on January 22, to mark 50th Anniversary and to underscore its role as a key player in Jordan’s pharmaceutical industry.
The company, which exports over 250 pharmaceutical products to more than 40 countries, employs 760 people, 30% of whom are women.
